Apoteket (A) Q1 2026 earnings summary

Executive summary

• Net sales increased by 17.0% year-over-year to SEK 7,514 million, driven by strong growth in both consumer and healthcare segments, especially from a new contract with Region Skåne.

• Operating income rose to SEK 128 million from SEK 119 million, with a slightly lower margin of 1.7% due to new healthcare operations and higher average prices on prescribed drugs.

• Net income for the period was SEK 159 million, up from SEK 151 million year-over-year.

• E-commerce continued to grow, and three new physical pharmacies were opened in smaller towns.

• Sustainability efforts were recognized with several awards for perceived sustainability, customer empathy, and responsibility.

Financial highlights

• Net sales: SEK 7,514 million (up from SEK 6,424 million year-over-year).

• Operating income: SEK 128 million (up from SEK 119 million year-over-year).

• Operating margin: 1.7% (down from 1.9% year-over-year).

• Net income: SEK 159 million (up from SEK 151 million year-over-year).

• Operating cash flow: SEK -22 million (down from SEK 44 million year-over-year), impacted by higher working capital needs.

• Investments: SEK 31 million, mainly in store fittings and tech solutions.

Outlook and guidance

• Long-term target for operating margin is 3.0%; current rolling 12-month margin is 2.0%.

• Solidarity target is 35-45%; current level is 42.9%.

• Dividend policy: 40-60% of annual result adjusted for pension effects; SEK 271 million dividend for 2025 approved.